This article presents recent findings and perspectives on the relationship between early-life respiratory infections and asthma inception, and discusses emerging concepts on strategies that target these infectious agents for asthma prevention.
INTRODUCTION
Infection-related wheezing in early childhood is common and may be the first presentation of asthma. Much research has focused on the role of early-life respiratory syncytial virus (RSV) and human rhinovirus (HRV) infections in asthma inception. In addition, emerging data suggest that the composition of the airway microbiome in early life and virus-bacteria interactions are important determinants of future asthma. This review summarizes recent findings regarding the role of early-life infections in asthma inception, and how interventions directed against these infectious agents may allow asthma prevention.
THE ROLE OF EARLY-LIFE RESPIRATORY VIRAL INFECTIONS IN ASTHMA INCEPTION

Respiratory syncytial virus
Early-life severe RSV bronchiolitis confers substantial risk for subsequent wheezing and asthma development [1] [2] [3] [4] [5] . For the purpose of this review, we will use the term 'severe RSV bronchiolitis' to refer to an episode of bronchiolitis requiring hospitalization. The highest rates of asthma development following severe RSV bronchiolitis have been reported in the RSV Bronchiolitis in Early Life study, a prospective cohort of infants hospitalized for RSV bronchiolitis [5] . By their 7th birthday, almost half of these infants had a physician diagnosis of asthma [5] . A more recent prospective European study [6] has also demonstrated the high prevalence of asthma following severe RSV bronchiolitis, with 21% of infants hospitalized for RSV bronchiolitis having asthma at age 6 years compared with 5% of a control cohort. Early-life hospitalization for RSV bronchiolitis was also associated with the development of obstructive pattern in pulmonary function testing and elevated FeNO levels [6] .
There is direct relationship between the risk of future asthma and the severity of the initial RSV lower respiratory tract infection (LRTI), with the greatest risk of asthma following episodes that required hospitalization [7, 8] . This severity-outcome association may explain the observation that increased asthma risk persisted into early adulthood in a cohort of children hospitalized in infancy for RSV LRTI [9] ; whereas among children who had less severe RSV bronchiolitis, with predominantly outpatient episodes, this association diminished with age and became nonsignificant by the age of 13 years [10] . Environmental factors may augment asthma risk, even among children who had less severe disease not requiring hospitalization: young adults who experienced generally mild RSV LRTI in early life were more likely to have current asthma if they became active smokers [11 & ]. The authors suggested that airway abnormalities preexisting RSV LRTI and/or airway damage caused by RSV may increase susceptibility to active cigarette smoking, which results in asthma [11 & ]. A detailed description of mechanisms that may mediate the progression from severe RSV LRTI to asthma is beyond the scope of this review and they are discussed elsewhere [12 & ,13,14 & ].
Human rhinovirus
Advances in virologic detection techniques have led to the identification of early-life HRV LRTI (especially HRV-C) as a very important determinant of future asthma. Insightful data on the role of HRV in the inception of asthma have originated from Childhood Origin of Asthma study [15] , a birth cohort of children at high risk for allergic diseases and/or asthma. Early-life HRV-associated wheezing LRTIs (mostly outpatient episodes) were a significant predictor of asthma at age 6 years [16] and of an obstructive lung function pattern at age 5-8 years [17] . In this cohort, asthma risk was much higher after HRV LRTI compared with the risk following RSV LRTI [16] . Similar findings were obtained from the Australian Childhood Asthma Study (CAS), a birth cohort of infants at high risk of atopy [18] . However, it should be noted that these two cohorts comprised children at high risk of developing asthma; therefore, these findings may not necessarily be generalizable to other populations. Nevertheless, these findings highlight the importance of early-life HRV LRTI in asthma pathogenesis in these populations. Furthermore, the highest risk for future asthma was detected among children with genetic variants in an asthma-associated gene locus on chromosome 17 (17q21) who experienced early-life HRV wheezing illnesses, highlighting the importance of interactions between the child's genetic background, and the viral infection [19] .
RESPIRATORY SYNCYTIAL VIRUS AND HUMAN RHINOVIRUS MAY HAVE DIFFERENT ROLES IN ASTHMA PATHOGENESIS: IMPLICATIONS FOR PREVENTION STRATEGIES
Despite intensive investigation, it remains uncertain if severe early-life viral LRTI causes future asthma by causing airway epithelial injury and/or creating the appropriate proinflammatory allergenic milieu that with a subsequent allergen exposure, in the appropriate time frame, could result in allergic airway inflammation and asthma; or whether the wheezing viral LRTI serves as a marker for asthma susceptibility among children with the appropriate genetic background [20 && ,21]. Children who have their initial wheeze during HRV illnesses differ from those who experience their initial wheeze during RSV LRTI: they tend to have personal and family history of asthma, and are usually older [20 && ,22]. These differences may be related, at least in part, to different study designs, but may also suggest that the initial wheezing HRV LRTI may serve as a marker for asthma tendency, whereas early-life RSV bronchiolitis (especially the severe episodes) may have a causative role in asthma inception. The potential causal role of RSV infection in asthma inception is supported by the finding that treatment of late preterm infants, during the RSV season, with the anti-RSV monoclonal antibody
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palivizumab, resulted in reductions in the occurrence of RSV bronchiolitis and the number of wheezing days during the first year of life even following the treatment period [23] . These results suggest that primary prevention of RSV bronchiolitis may be an effective strategy to prevent post-RSV recurrent wheeze and potentially asthma [23] .
The presence of atopy (personal or family) has a role in the development of post-RSV asthma, as maternal asthma was a risk factor for a more severe RSV bronchiolitis [24] and for the development of post-RSV asthma [5] . Atopic predisposition is also a very significant risk factor for the development of asthma following HRV LRTI. This concept was shown in two reports demonstrating that atopy among children who wheeze with HRV may modify their asthma risk. Having a mother with atopic asthma significantly increased the infant's risk of having HRV LRTI compared with RSV LRTI; and having a mother with asthma increased the severity of infant HRV but not RSV LRTI [25] . Moreover, the sequence of acquisition of allergic sensitization and experiencing HRV wheezing is nonrandom, as sensitization to aeroallergens preceded, and was a significant risk factor for, HRV wheezing illness [26] , whereas having an HRV wheezing illness was not a risk factor for the development of allergic sensitization. This sequence of events was confirmed in a report from the CAS high-risk birth cohort, where LRTI associated-wheeze was associated with the presence of HRV (mainly HRV-C), but only in high-risk children who developed allergic sensitization during infancy [27 && ]. Collectively, these results suggest that HRV wheezing illness followed, rather than predisposed to, the development of atopy, at least children who are at high risk for asthma/ atopy development.
These potential differences in the contributions of RSV vs HRV LRTI to subsequent asthma risk suggest the need for potentially virus-specific strategies for asthma prevention. As evidence suggest RSV's probably has a causal role in the development of asthma, prevention of RSV infection and/or attenuation of RSV illness severity and/or the associated inflammatory response may reduce the risk of subsequent asthma. On the other hand, as allergic sensitization precedes HRV LRTI, prevention of the development of allergic sensitization among young children may prevent HRV LRTI, and thus may also reduce the likelihood of asthma.
Finally, although studies to date have focused on the role of specific viruses (i.e. RSV and HRV) causing the initial wheezing illness and in asthma inception, it is likely that these two pathways are not independent. Given the necessity for multiple wheezing episodes, most of which occur in the setting of viral infections, to precede an asthma diagnosis, the outcome of childhood asthma is likely to follow occurrence of multiple viral-associated wheezing episodes because of multiple different viruses. More research on this topic is needed, but results of a recent study [28] support this concept by reporting that the number of RTIs in early life, but not the specific viral trigger, was associated with development of asthma at school age.
THE ROLE OF THE AIRWAY MICROBIOME IN ASTHMA INCEPTION
Airway bacterial presence and asthma inception
In addition to the long-established association between early-life viral respiratory infections and subsequent asthma [20
&&
,21], bacterial microbes are detectable in the airway and comprise the airway microbiome, have recently emerged as significant contributors to asthma inception and exacerbation [29] . The contribution of the airway microbiome to asthma inception should be viewed in the broader context of the effects of the environmental and enteral microbiomes on the immune system, as exposure to a wide range of microbes has been found to be protective against asthma development. These topics are reviewed by Drs Boushey and Lynch in this issue of the journal (165-171).
Asymptomatic bacterial colonization of the hypopharynx at the age of 1 month was associated with higher risk of developing persistent wheezing and asthma [30] . Moreover, bacteria, either as an isolated pathogen or together with a virus, were identified in 86% of wheezing episodes during the first 3 years of life [31 & ]. The authors suggested that the commonly used term 'viral wheeze' is inappropriate as it underestimates the role of bacteria in the pathophysiology of these wheezing episodes [31 & ].
A subsequent nested-case-control study from this group provides additional mechanistic rationale to explain the role of airway bacteria in asthma inception. The investigators compared the immune responses to H. influenzae, M. catarrhalis, and S. pneumoniae, in peripheral blood mononuclear cells obtained at the age of 6 months, between children who were subsequently diagnosed with asthma at the age of 7 years and children who did not develop asthma [32 & ]. Children who eventually developed asthma had an aberrant early-life immune response evident by increased IL-5, IL-13, IL-17, and IL-10 production. The investigators hypothesized that aberrant immune response to pathogenic bacteria in the airways may predispose to persistent airway colonization of the bacteria, which in turn may result in Th-2 chronic airway inflammation, and eventually asthma [32 & ]. However, the exact direction of the association between early-life airway colonization with bacteria and the aberrant immune response is yet to be determined.
Bacteria-virus interactions and the inception of asthma
The ability to characterize airway bacterial communities using genetic based techniques has highlighted the importance of bacteria and virus interplay in asthma inception and exacerbations. Kloepfer et al. [33] performed viral studies and PCR for common airway bacteria in upper-airway samples obtained weekly from school-aged children with and without asthma during the peak HRV season. HRV infection predisposed to subsequent airway bacterial infection and/or colonization. Furthermore, the presence of M. catarrhalis and S. pneumoniae in the airway contributed to the severity of respiratory tract illnesses, including asthma exacerbations [33] . The investigators proposed that the secondary bacterial infections, potentially caused by disruption of the mucosal barrier by the virus, may augment the ongoing inflammatory response and could result in asthma exacerbation.
Another recent report provided valuable information on the composition of the bacterial and viral airway microbiomes during health and disease periods, during the first year of life, and their relationship with the development of chronic wheeze [27 && ]. The investigators performed 16S sequencing and screened for the presence of common respiratory viruses in nasopharyngeal samples collected during the first year of life at well visits and during acute respiratory infections (ARI) among participants of the CAS [18] . The upper-airway microbiome in infancy was found to have a simple structure dominated by only six genera, and each genus was dominated by a single species. Staphylococcus, Corynebacterium, and Alloiococcus dominated the samples taken during well visits, and could be viewed as the component of a 'healthy' airway microbiome, whereas Streptococcus, Moraxella, and Haemophilus became more dominant during viral ARIs [27 && ]. These findings are similar to a previous report on this topic [34] . Environmental factors shaped the microbiome structure, as antibiotic use and day-care attendance significantly selected for more 'pathogenic' bacteria in 'well samples'. Furthermore, the airway microbiome composition during viral infections affected the severity of ARI and the likelihood of progression to lower respiratory symptoms [27 && ]. Specifically, the presence of Streptococcus, Moraxella, and Haemophilus (collectively or individually) during RSV (but not HRV) infection was associated with progression from URI to LRTI. A specific interaction was noted between Moraxella and RSV, as the presence of Moraxella during RSV LRTI was associated with a more severe RSV infection evidenced by concomitant fever. The following risk factors were identified for chronic wheeze at age of 5 years: asymptomatic high-abundance colonization with Streptococcus before the age of 2 months, febrile LRTI, HRV wheeze, but only among infants who developed early-life sensitization, and young age at the time of first febrile LRTI [27 && ]. Finally, a potential causal pathway linking antibiotic use to later asthma was proposed: antibiotic use in infants may select for illness-associated bacteria in the airway microbiome, leading to increased risk of febrile LRTI, which in turn is associated with asthma development.
INFECTIOUS AGENTS: TARGETS FOR ASTHMA PREVENTION
Given the strong associations between early-life respiratory infection and subsequent asthma, strategies which either prevent the development of early-life respiratory infections or attenuate the severity of infection and the consequences of the immune response to the pathogen may lead to reductions in asthma risk. HRV therapeutics are currently not available mainly because of objective obstacles related to the complex structure of this virus [22] . However, numerous RSV vaccines and antiviral are currently in development [35 & ]. This section highlights some of the recent advancements in this field.
Active and passive respiratory syncytial virus vaccines
As noted above, the prevention of severe RSV LRTI utilizing palivizumab resulted in reduction in recurrent wheeze during the 1st year of life [23] . These results support the potential causative role of RSV infection in asthma inception, and provide encouragement that post-RSV asthma may be preventable, which may result in significant reduction in new asthma cases [36] . However, the substantial expense of palivizumab, the need to treat a broad population early in life and prior to acquisition of RSV infection, and the need for parenteral administration limit its widespread use. Therefore, there is a need for additional RSV therapeutics that overcome these limitations.
Primary prevention of respiratory syncytial virus infection via early-life active immunization
Efforts to develop an effective RSV vaccine have continued since the 1960s but, until recently, were generally unsuccessful or even harmful [37] . A major recent advancement in this field includes the utilization of a structure-based approach to develop an innovative RSV vaccine directed against a specific antigenic site of the RSV fusion (F) glycoprotein, a target of RSV-neutralizing antibodies [38] . This vaccine has shown promising results in mice studies [38] . Moreover, a genetically engineered, live-attenuated vaccine was effective in a phase 1 study [39 & ] in children and adults in producing neutralizing antibodies and to preventing illnesses.
Respiratory syncytial virus antiviral therapies
Currently, ribavirin is the only antiviral therapy available for RSV; however, its utilization is limited by modest efficacy and side-effects. Development of new antiviral medications is ongoing and recent studies have reported that the use of an oral RSVcell-entry inhibitor [40] and an oral nucleoside analogue [41] among healthy adults resulted in faster reduction of RSV load accompanied with a reduction in disease severity. Given the association between the severity of the acute RSV infection and post-RSV asthma, the attenuation of disease severity by such RSV therapeutics could reduce in the risk of post-RSV asthma.
Attenuation of the inflammatory response during the acute respiratory syncytial virus lower respiratory tract infection
As there is no cost-effective, broadly available, simple therapeutic option capable of preventing severe RSV bronchiolitis, there is an ongoing need for an intervention capable of modifying the outcomes of post-RSV asthma. Based on the antiinflammatory properties of azithromycin in other inflammatory airway diseases [42] and our previous findings in a murine model of viral bronchiolitis [43] , we performed a proof-of-concept, doubleblinded, randomized trial in 40 infants hospitalized with RSV bronchiolitis investigating the utility of adding 2 weeks of azithromycin therapy to routine bronchiolitis care. Infants who received azithromycin had a significant lower likelihood if developing recurrent wheeze and had fewer days with respiratory symptoms over the subsequent year [44 && ]. Anti-inflammatory effects may have mediated some of the beneficial effects of azithromycin, as azithromycin reduced levels of upper-airway IL-8, a major neutrophil chemoattractant [44 && ]. However, and in contrast to previous in-vitro reports [45, 46] , we did not detect a reduction in viral load among children treated with azithromycin [47] . 
Prevention of posthuman rhinovirus wheezing
A recent trial suggested that systemic corticosteroids may prevent the respiratory sequelae of post-RSV wheezing in a subset of children presenting with high HRV loads in the airway. Toddlers presenting in the first HRV wheeze episode were randomized to receive oral prednisolone or placebo for 4 days [48 & ]. Overall, there was no difference between the groups in the primary outcomes: wheezing occurrences and initiation of asthma controller medication within 12 months [48 & ]. However, a stratified analysis showed that children with high HRV loads who were treated with prednisolone had longer time to the next wheezing episode over the following 12 months. The investigators hypothesized that high HRV load is a marker for significant airway inflammation, which identifies children who may benefit from oral corticosteroids therapy given as a modifier of the short-term respiratory sequel of post-HRV wheeze [48 & ]. It is still unknown if this intervention provides long-term impact, and studies with longer follow-up periods are needed to address this question.
CONCLUSION
Current evidence supports the major roles of earlylife RSV and HRV infections in asthma inception. Asthma prevention approaches targeting these viral triggers may need to differ according to the specific causative virus leading to the initial wheezing LRTI episode. The airway microbiome composition in early life and bacteria-virus interactions has emerged as relevant determinants of childhood asthma (Fig. 1 ). Emerging data have shown that species of the Streptococcus, Moraxella, and Haemophilus genera are associated with respiratory illnesses and with asthma development; hence, airway microbiome modifications, which specifically target these bacteria, should be pursued as potential asthma prevention strategies. Finally, interventions aimed at preventing early-life respiratory infections and/or attenuating the inflammatory response during the acute illness are currently under intense research and development, and may allow us to achieve the ultimate goal of prevention of childhood asthma.
